BioAtla (BCAB) EBT Margin (2020 - 2026)

BioAtla's (BCAB) quarterly EBT Margin came in at 3.57% in Q2 2026, up 100.78% quarter-over-quarter from 459.1% in Q4 2025.

Analysis

BioAtla (BCAB) EBT Margin (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported EBT Margin for 5 consecutive years, with 3.57% the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, EBT Margin changed N/A year-over-year to 3.57%; the trailing twelve-month figure through Jun 2026 stood at 375.29% (up 18747.0% YoY), and the FY2025 full-year result was 2923.1%, down 228152.0% from the prior year.
EBT Margin improved to 3.57% in Q2 2026 per BCAB's latest filing, from 459.1% in the prior quarter.
Across five years, EBT Margin topped out at 3.57% in Q2 2026 and bottomed at 459.1% in Q4 2025.
Historically, EBT Margin has averaged 183.92% across 3 years, with a median of 96.24% in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn	27.53%
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn	-131.41%
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn	41.75%
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn	35.61%
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn	35.78%
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn	-528.97%
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn	13.77%
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn	4.84%
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn	-2.67%
10	BioAtla	2.33 Mn	2.33 Mn	-	3.57%

Historic Data

Download Data